Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.
Authors Higashi Mitchell K; Veenstra David L; Kondo L Midori; Wittkowsky Ann K; Srinouanprachanh Sengkeo L; Farin Fred M; Rettie Allan E;
JournalJAMA
PubMed ID11926893
Edited for space constraints: Warfarin is a commonly used anticoagulant that requires careful clinical management to balance the risks of overanticoagulation and bleeding with those of underanticoagulation and clotting. The principal enzyme involved in warfarin metabolism is CYP2C9, and 2 relatively common variant forms with reduced activity have been identified, ... More
Authors Collard Charles D; Park Kellie A; Montalto Michael C; Alapati Sailaja; Buras Jon A; Stahl Gregory L; Colgan Sean P;
JournalJ Biol Chem
PubMed ID11847215
Endothelial barrier function is altered by the release of soluble polymorphonuclear leukocyte (PMN)-derived mediators during inflammatory states. However, endogenous pathways to describe such changes are only recently appreciated. Using an in vitro endothelial paracellular permeability model, cell-free supernatants from formylmethionylleucylphenylalanine-stimulated PMNs were observed to significantly alter endothelial permeability. Biophysical and ... More